Recruiting
Phase 3

Sponsor:

KalVista Pharmaceuticals, Ltd.

Code:

NCT06467084

Conditions

Hereditary Angioedema

Eligibility Criteria

Sex: All

Age: 2 - 11

Healthy Volunteers: Not accepted

Interventions

KVD900 75 mg

KVD900 150 mg

KVD900 300 mg

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-01. This information was provided to ClinicalTrials.gov by KalVista Pharmaceuticals, Ltd. on 2025-04-11.